Paltusotine

A nonpeptide somatostatin receptor agonist

Paltusotine
[[File: Chemical structure of Paltusotine |frameless|220px|alt=|]]
INN
Drug class	Somatostatin receptor agonist
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Investigational
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Paltusotine is an investigational drug that acts as a nonpeptide somatostatin receptor agonist. It is primarily being developed for the treatment of acromegaly, a disorder characterized by excessive production of growth hormone (GH), and potentially for other conditions related to hormonal dysregulation.

Mechanism of Action

Paltusotine functions by selectively targeting and activating the somatostatin receptor subtype 2 (SST2). This receptor is involved in the inhibition of growth hormone secretion. By mimicking the action of the natural hormone somatostatin, paltusotine reduces the levels of circulating growth hormone and insulin-like growth factor 1 (IGF-1), which are typically elevated in patients with acromegaly.

Development and Clinical Trials

Paltusotine is being developed by Crinetics Pharmaceuticals. It is currently undergoing clinical trials to evaluate its efficacy and safety in patients with acromegaly. The drug is administered orally, which is a significant advantage over existing therapies that often require injections.

Phase 1 Trials

Initial Phase 1 clinical trials focused on assessing the safety, tolerability, and pharmacokinetics of paltusotine in healthy volunteers. These studies helped establish the appropriate dosing regimen for subsequent trials.

Phase 2 Trials

In Phase 2 clinical trials, paltusotine was tested in patients with acromegaly to determine its effectiveness in reducing GH and IGF-1 levels. The results indicated that paltusotine effectively lowered these hormone levels, suggesting potential as a treatment option for acromegaly.

Potential Benefits

The development of paltusotine as an oral medication offers several potential benefits over existing treatments for acromegaly, which often involve injectable somatostatin analogs. Oral administration improves patient compliance and quality of life by eliminating the need for frequent injections.

Future Directions

Further research is needed to explore the long-term effects of paltusotine and its potential applications in other conditions associated with hormonal imbalances. Ongoing and future clinical trials will provide more data on its safety profile and therapeutic efficacy.

Related Pages

• Acromegaly
• Somatostatin
• Growth hormone
• Insulin-like growth factor 1
• Somatostatin receptor